<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jin X</submitter><funding>Shanghai Natural Science Foundation Project</funding><funding>National Natural Science Foundation of China</funding><funding>National Key Kesearch and Development Plan of the Ministry of Science and Technology</funding><funding>the Public Health Bureau Foundation of Shanghai</funding><pagination>42</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11040978</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The integration of transcriptomic, proteomic, druggable genetic and metabolomic association studies facilitated a comprehensive investigation of molecular features and shared pathways for cancers' development and progression.&lt;h4>Methods&lt;/h4>Comprehensive approaches consisting of transcriptome-wide association studies (TWAS), proteome-wide association studies (PWAS), summary-data-based Mendelian randomization (SMR) and MR were performed to identify genes significantly associated with cancers. The results identified in above analyzes were subsequently involved in phenotype scanning and enrichment analyzes to explore the possible health effects and shared pathways. Additionally, we also conducted MR analysis   to investigate metabolic pathways related to cancers.&lt;h4>Results</pubmed_abstract><journal>Human genomics</journal><pubmed_title>Prioritization of therapeutic targets for cancers using integrative multi-omics analysis.</pubmed_title><pmcid>PMC11040978</pmcid><funding_grant_id>201940043</funding_grant_id><funding_grant_id>2022YFE0125300</funding_grant_id><funding_grant_id>81874056</funding_grant_id><funding_grant_id>202240240</funding_grant_id><funding_grant_id>22ZR1413300</funding_grant_id><funding_grant_id>81874182</funding_grant_id><pubmed_authors>Wang M</pubmed_authors><pubmed_authors>Jiang Z</pubmed_authors><pubmed_authors>Jin X</pubmed_authors><pubmed_authors>Mei Y</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>He X</pubmed_authors><pubmed_authors>Yang P</pubmed_authors><pubmed_authors>Zhu W</pubmed_authors><pubmed_authors>Huang R</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prioritization of therapeutic targets for cancers using integrative multi-omics analysis.</name><description>&lt;h4>Background&lt;/h4>The integration of transcriptomic, proteomic, druggable genetic and metabolomic association studies facilitated a comprehensive investigation of molecular features and shared pathways for cancers' development and progression.&lt;h4>Methods&lt;/h4>Comprehensive approaches consisting of transcriptome-wide association studies (TWAS), proteome-wide association studies (PWAS), summary-data-based Mendelian randomization (SMR) and MR were performed to identify genes significantly associated with cancers. The results identified in above analyzes were subsequently involved in phenotype scanning and enrichment analyzes to explore the possible health effects and shared pathways. Additionally, we also conducted MR analysis   to investigate metabolic pathways related to cancers.&lt;h4>Results</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-01T21:54:41.41Z</modification><creation>2025-04-06T03:15:08.928Z</creation></dates><accession>S-EPMC11040978</accession><cross_references><pubmed>38659038</pubmed><doi>10.1186/s40246-024-00571-2</doi></cross_references></HashMap>